Current Report Filing (8-k)
May 25 2023 - 3:06PM
Edgar (US Regulatory)
0001857044
false
0001857044
2023-05-25
2023-05-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) May
25, 2023
INDAPTUS
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40652 |
|
86-3158720 |
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
3
Columbus Circle 15th Floor |
|
|
New
York |
|
10019 |
(Address of principal executive
offices) |
|
(Zip Code) |
(646)
427-2727
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities
registered pursuant to Section 12(b) of the Act: |
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, $0.01 par value |
|
INDP |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07. Submission of Matters to a Vote of Security Holders.
On
May 25, 2023, Indaptus Therapeutics, Inc. (the “Company”) held its 2023 annual meeting of stockholders (the “Meeting”).
A total of 4,469,519 shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”), were
present in person or represented by proxy at the Meeting, representing approximately 53% of the Company’s outstanding Common Stock
as of the March 31, 2023 record date. The following are the voting results for the proposals considered and voted upon at the Meeting,
each of which were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April
12, 2023.
Proposal
1. Election of two Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held
in 2026 and until their respective successors have been duly elected and qualified or until each such director’s earlier death,
resignation or removal.
| |
Votes FOR | | |
Votes WITHHELD | | |
Broker Non-Votes | |
William B. Hayes | |
| 2,452,279 | | |
| 122,117 | | |
| 1,895,123 | |
Anthony Maddaluna | |
| 2,544,652 | | |
| 29,744 | | |
| 1,895,123 | |
Proposal
2. Ratification of the appointment of Haskell & White LLP as the Company’s independent registered public accounting
firm for the fiscal year ending December 31, 2023.
Votes FOR | | |
Votes AGAINST | | |
Votes ABSTAINED | | |
Broker Non-Votes | |
| 4,446,392 | | |
| 22,167 | | |
| 960 | | |
| N/A | |
Based
on the foregoing votes, William B. Hayes and Anthony Maddaluna were elected as Class II directors, and Proposal 2 was approved.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
INDAPTUS
THERAPEUTICS, INC. |
|
|
|
Date:
May 25, 2023 |
By: |
/s/
Nir Sassi |
|
Name:
|
Nir
Sassi |
|
Title: |
Chief
Financial Officer |
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024